 | • レポートコード：QYR9ST01634 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品・医療 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※本調査レポートでは、世界の神経内分泌癌市場について調査・分析し、以下の構成でお届け致します。神経内分泌癌の種類別には、化学療法、ソマトスタチンアナログ、標的療法に、用途別には、病院、クリニック、腫瘍センター、外来手術センターに、地域別には、北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカなどに区分してセグメント分析を行いました。 ・調査販売 ・エグゼクティブ・サマリー ・企業別神経内分泌癌売上データ ・地域別神経内分泌癌市場規模：北米、アメリカ、ヨーロッパ、アジア、中国、日本国内、韓国、インド、中南米、中東・アフリカ、その他 ・種類別神経内分泌癌市場規模：化学療法、ソマトスタチンアナログ、標的療法 ・用途別神経内分泌癌市場規模：病院、クリニック、腫瘍センター、外来手術センター ・主要メーカーの企業情報：Pfizer、Novartis、Chiasma、Ipsen、Abbvie、Valeant、Jubilant、Teva、F.Hoffmann-La Roche、Advanced Accelerator、Mateon、Lexicon ・神経内分泌癌の市場規模予測 ・バリューチェーン及び販売チャネル分析 ・市場機会・課題・リスク・影響因子分析 ... |
Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous systems. Many are benign, while some are malignant. They most commonly occur in the intestine, where they are often called carcinoid tumors, but they are also found in the pancreas, lung and the rest of the body.The somatostatin analogs segment by treatment type is expected to witness high traction in the coming years.
The global Neuroendocrine Carcinoma market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Neuroendocrine Carcinoma market based on company, product type, end user and key regions.
This report studies the global market size of Neuroendocrine Carcinoma in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Neuroendocrine Carcinoma in these regions.
This research report categorizes the global Neuroendocrine Carcinoma market by top players/brands, region, type and end user. This report also studies the global Neuroendocrine Carcinoma market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer
Novartis
Chiasma
Ipsen
Abbvie
Valeant
Jubilant
Teva
F.Hoffmann-La Roche
Advanced Accelerator
Mateon
Lexicon
Market size by Product
Chemotherapy
Somatostatin Analogs
Targeted Therapy
Market size by End User
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Neuroendocrine Carcinoma market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Neuroendocrine Carcinoma market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Neuroendocrine Carcinoma companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Neuroendocrine Carcinoma submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Neuroendocrine Carcinoma are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Neuroendocrine Carcinoma market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
レポート目次Table of Contents
1 Study Coverage
1.1 Neuroendocrine Carcinoma Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by Product
1.4.2 Chemotherapy
1.4.3 Somatostatin Analogs
1.4.4 Targeted Therapy
1.5 Market by End User
1.5.1 Global Neuroendocrine Carcinoma Market Size Growth Rate by End User
1.5.2 Hospital
1.5.3 Clinics
1.5.4 Oncology Centres
1.5.5 Ambulatory Surgery Centres
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Neuroendocrine Carcinoma Market Size
2.1.1 Global Neuroendocrine Carcinoma Revenue 2014-2025
2.1.2 Global Neuroendocrine Carcinoma Sales 2014-2025
2.2 Neuroendocrine Carcinoma Growth Rate by Regions
2.2.1 Global Neuroendocrine Carcinoma Sales by Regions
2.2.2 Global Neuroendocrine Carcinoma Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Neuroendocrine Carcinoma Sales by Manufacturers
3.1.1 Neuroendocrine Carcinoma Sales by Manufacturers
3.1.2 Neuroendocrine Carcinoma Sales Market Share by Manufacturers
3.1.3 Global Neuroendocrine Carcinoma Market Concentration Ratio (CR5 and HHI)
3.2 Neuroendocrine Carcinoma Revenue by Manufacturers
3.2.1 Neuroendocrine Carcinoma Revenue by Manufacturers (2014-2019)
3.2.2 Neuroendocrine Carcinoma Revenue Share by Manufacturers (2014-2019)
3.3 Neuroendocrine Carcinoma Price by Manufacturers
3.4 Neuroendocrine Carcinoma Manufacturing Base Distribution, Product Types
3.4.1 Neuroendocrine Carcinoma Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Neuroendocrine Carcinoma Product Type
3.4.3 Date of International Manufacturers Enter into Neuroendocrine Carcinoma Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Neuroendocrine Carcinoma Sales by Product
4.2 Global Neuroendocrine Carcinoma Revenue by Product
4.3 Neuroendocrine Carcinoma Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Neuroendocrine Carcinoma Breakdown Data by End User
6 North America
6.1 North America Neuroendocrine Carcinoma by Countries
6.1.1 North America Neuroendocrine Carcinoma Sales by Countries
6.1.2 North America Neuroendocrine Carcinoma Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Neuroendocrine Carcinoma by Product
6.3 North America Neuroendocrine Carcinoma by End User
7 Europe
7.1 Europe Neuroendocrine Carcinoma by Countries
7.1.1 Europe Neuroendocrine Carcinoma Sales by Countries
7.1.2 Europe Neuroendocrine Carcinoma Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Neuroendocrine Carcinoma by Product
7.3 Europe Neuroendocrine Carcinoma by End User
8 Asia Pacific
8.1 Asia Pacific Neuroendocrine Carcinoma by Countries
8.1.1 Asia Pacific Neuroendocrine Carcinoma Sales by Countries
8.1.2 Asia Pacific Neuroendocrine Carcinoma Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Neuroendocrine Carcinoma by Product
8.3 Asia Pacific Neuroendocrine Carcinoma by End User
9 Central & South America
9.1 Central & South America Neuroendocrine Carcinoma by Countries
9.1.1 Central & South America Neuroendocrine Carcinoma Sales by Countries
9.1.2 Central & South America Neuroendocrine Carcinoma Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Neuroendocrine Carcinoma by Product
9.3 Central & South America Neuroendocrine Carcinoma by End User
10 Middle East and Africa
10.1 Middle East and Africa Neuroendocrine Carcinoma by Countries
10.1.1 Middle East and Africa Neuroendocrine Carcinoma Sales by Countries
10.1.2 Middle East and Africa Neuroendocrine Carcinoma Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Neuroendocrine Carcinoma by Product
10.3 Middle East and Africa Neuroendocrine Carcinoma by End User
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Details
11.1.2 Company Business Overview
11.1.3 Pfizer Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Pfizer Neuroendocrine Carcinoma Products Offered
11.1.5 Pfizer Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Company Business Overview
11.2.3 Novartis Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Novartis Neuroendocrine Carcinoma Products Offered
11.2.5 Novartis Recent Development
11.3 Chiasma
11.3.1 Chiasma Company Details
11.3.2 Company Business Overview
11.3.3 Chiasma Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Chiasma Neuroendocrine Carcinoma Products Offered
11.3.5 Chiasma Recent Development
11.4 Ipsen
11.4.1 Ipsen Company Details
11.4.2 Company Business Overview
11.4.3 Ipsen Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Ipsen Neuroendocrine Carcinoma Products Offered
11.4.5 Ipsen Recent Development
11.5 Abbvie
11.5.1 Abbvie Company Details
11.5.2 Company Business Overview
11.5.3 Abbvie Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Abbvie Neuroendocrine Carcinoma Products Offered
11.5.5 Abbvie Recent Development
11.6 Valeant
11.6.1 Valeant Company Details
11.6.2 Company Business Overview
11.6.3 Valeant Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Valeant Neuroendocrine Carcinoma Products Offered
11.6.5 Valeant Recent Development
11.7 Jubilant
11.7.1 Jubilant Company Details
11.7.2 Company Business Overview
11.7.3 Jubilant Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Jubilant Neuroendocrine Carcinoma Products Offered
11.7.5 Jubilant Recent Development
11.8 Teva
11.8.1 Teva Company Details
11.8.2 Company Business Overview
11.8.3 Teva Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Teva Neuroendocrine Carcinoma Products Offered
11.8.5 Teva Recent Development
11.9 F.Hoffmann-La Roche
11.9.1 F.Hoffmann-La Roche Company Details
11.9.2 Company Business Overview
11.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
11.9.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Products Offered
11.9.5 F.Hoffmann-La Roche Recent Development
11.10 Advanced Accelerator
11.10.1 Advanced Accelerator Company Details
11.10.2 Company Business Overview
11.10.3 Advanced Accelerator Neuroendocrine Carcinoma Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Advanced Accelerator Neuroendocrine Carcinoma Products Offered
11.10.5 Advanced Accelerator Recent Development
11.11 Mateon
11.12 Lexicon
12 Future Forecast
12.1 Neuroendocrine Carcinoma Market Forecast by Regions
12.1.1 Global Neuroendocrine Carcinoma Sales Forecast by Regions 2019-2025
12.1.2 Global Neuroendocrine Carcinoma Revenue Forecast by Regions 2019-2025
12.2 Neuroendocrine Carcinoma Market Forecast by Product
12.2.1 Global Neuroendocrine Carcinoma Sales Forecast by Product 2019-2025
12.2.2 Global Neuroendocrine Carcinoma Revenue Forecast by Product 2019-2025
12.3 Neuroendocrine Carcinoma Market Forecast by End User
12.4 North America Neuroendocrine Carcinoma Forecast
12.5 Europe Neuroendocrine Carcinoma Forecast
12.6 Asia Pacific Neuroendocrine Carcinoma Forecast
12.7 Central & South America Neuroendocrine Carcinoma Forecast
12.8 Middle East and Africa Neuroendocrine Carcinoma Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Neuroendocrine Carcinoma Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Figure Neuroendocrine Carcinoma Product Picture
Table Neuroendocrine Carcinoma Market Segments
Table Key Manufacturers Neuroendocrine Carcinoma Covered
Table Global Neuroendocrine Carcinoma Market Size Growth Rate by Product 2019-2025 (K Pcs) & (Million US$)
Figure Global Neuroendocrine Carcinoma Sales Market Share by Product 2014-2025
Figure Chemotherapy Product Picture
Table Major Manufacturers of Chemotherapy
Figure Somatostatin Analogs Product Picture
Table Major Manufacturers of Somatostatin Analogs
Figure Targeted Therapy Product Picture
Table Major Manufacturers of Targeted Therapy
Table Global Neuroendocrine Carcinoma Market Size Growth Rate by End User 2019-2025 (K Pcs)
Figure Hospital
Figure Clinics
Figure Oncology Centres
Figure Ambulatory Surgery Centres
Figure Neuroendocrine Carcinoma Report Years Considered
Figure Global Neuroendocrine Carcinoma Market Size 2014-2025 (Million US$)
Figure Global Neuroendocrine Carcinoma Sales 2014-2025 (K Pcs)
Table Global Neuroendocrine Carcinoma Market Size by Regions 2014-2019 (K Pcs) & (Million US$)
Table Global Neuroendocrine Carcinoma Sales by Regions 2014-2019 (K Pcs)
Table Global Neuroendocrine Carcinoma Sales Market Share by Regions 2014-2019
Figure Global Neuroendocrine Carcinoma Sales Market Share by Regions 2014-2019
Figure 2018 Global Neuroendocrine Carcinoma Sales Market Share by Regions
Table Global Neuroendocrine Carcinoma Revenue by Regions 2014-2019 (Million US$)
Table Global Neuroendocrine Carcinoma Revenue Market Share by Regions 2014-2019
Figure Global Neuroendocrine Carcinoma Revenue Market Share by Regions 2014-2019
Figure 2018 Global Neuroendocrine Carcinoma Revenue Market Share by Regions
Table Global Neuroendocrine Carcinoma Sales by Manufacturers (2014-2019) (K Pcs)
Table Global Neuroendocrine Carcinoma Sales Share by Manufacturers (2014-2019)
Figure Global Neuroendocrine Carcinoma Sales Share by Manufacturers in 2018
Table Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Neuroendocrine Carcinoma Revenue by Manufacturers (2014-2019) (Million USD)
Table Neuroendocrine Carcinoma Revenue Share by Manufacturers (2014-2019)
Figure Neuroendocrine Carcinoma Value Share by Manufacturers in 2018
Table Key Manufacturers Neuroendocrine Carcinoma Price (2014-2019) (USD/Pcs)
Table Neuroendocrine Carcinoma Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Neuroendocrine Carcinoma Product Type
Table Date of International Manufacturers Enter into Neuroendocrine Carcinoma Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Neuroendocrine Carcinoma Sales by Product (2014-2019) (K Pcs)
Table Global Neuroendocrine Carcinoma Sales Share by Product (2014-2019)
Figure Global Neuroendocrine Carcinoma Sales Market Share by Product (2014-2019)
Figure Global Neuroendocrine Carcinoma Sales Market Share by Product in 2018
Table Global Neuroendocrine Carcinoma Revenue by Product (2014-2019) (Million US$)
Table Global Neuroendocrine Carcinoma Revenue Share by Product (2014-2019)
Figure Global Neuroendocrine Carcinoma Revenue Market Share by Product (2014-2019)
Figure Global Neuroendocrine Carcinoma Revenue Market Share by Product in 2018
Table Neuroendocrine Carcinoma Price by Product 2014-2019 (USD/Pcs)
Table Global Neuroendocrine Carcinoma Sales by End User (2014-2019) (K Pcs)
Table Global Neuroendocrine Carcinoma Sales Share by End User (2014-2019)
Figure Global Sales Neuroendocrine Carcinoma Market Share by End User (2014-2019)
Figure Global Sales Neuroendocrine Carcinoma Market Share by End User in 2018
Figure North America Neuroendocrine Carcinoma Sales Growth Rate 2014-2019 (K Pcs)
Figure North America Neuroendocrine Carcinoma Revenue Growth Rate 2014-2019 (Million US$)
Table North America Neuroendocrine Carcinoma Sales by Countries (2014-2019) (K Pcs)
Table North America Neuroendocrine Carcinoma Sales Market Share by Countries (2014-2019)
Figure 2018 North America Neuroendocrine Carcinoma Sales Market Share by Countries
Table North America Neuroendocrine Carcinoma Revenue by Countries (2014-2019) (Million US$)
Table North America Neuroendocrine Carcinoma Revenue Market Share by Countries (2014-2019)
Figure 2018 North America Neuroendocrine Carcinoma Revenue Market Share by Countries
Figure United States Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure United States Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (K Pcs)
Figure Canada Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Canada Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Mexico Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Mexico Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Table North America Neuroendocrine Carcinoma Sales by Product (2014-2019) (K Pcs)
Table North America Neuroendocrine Carcinoma Sales Market Share by Product (2014-2019)
Figure 2018 North America Neuroendocrine Carcinoma Market Share by Product
Table North America Neuroendocrine Carcinoma Sales by End User (2014-2019) (K Pcs)
Table North America Neuroendocrine Carcinoma Sales Market Share by End User (2014-2019)
Figure 2018 North America Neuroendocrine Carcinoma Market Share by End User
Figure Europe Neuroendocrine Carcinoma Sales Growth Rate 2014-2019 (K Pcs)
Figure Europe Neuroendocrine Carcinoma Revenue Growth Rate 2014-2019 (Million US$)
Table Europe Neuroendocrine Carcinoma Sales by Countries (2014-2019) (K Pcs)
Table Europe Neuroendocrine Carcinoma Sales Market Share by Countries (2014-2019)
Figure 2018 Europe Neuroendocrine Carcinoma Sales Market Share by Countries
Table Europe Neuroendocrine Carcinoma Revenue by Countries (2014-2019) (Million US$)
Table Europe Neuroendocrine Carcinoma Revenue Market Share by Countries (2014-2019)
Figure 2018 Europe Neuroendocrine Carcinoma Revenue Market Share by Countries
Figure Germany Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Germany Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure France Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure France Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure UK Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure UK Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Italy Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Italy Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Russia Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Russia Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Table Europe Neuroendocrine Carcinoma Sales by Product (2014-2019) (K Pcs)
Table Europe Neuroendocrine Carcinoma Sales Market Share by Product (2014-2019)
Figure 2018 Europe Neuroendocrine Carcinoma Market Share by Product
Table Europe Neuroendocrine Carcinoma Sales by End User (2014-2019) (K Pcs)
Table Europe Neuroendocrine Carcinoma Sales Market Share by End User (2014-2019)
Figure 2018 Europe Neuroendocrine Carcinoma Market Share by End User
Figure Asia Pacific Neuroendocrine Carcinoma Sales Growth Rate 2014-2019 (K Pcs)
Figure Asia Pacific Neuroendocrine Carcinoma Revenue Growth Rate 2014-2019 (Million US$)
Table Asia Pacific Neuroendocrine Carcinoma Sales by Countries (2014-2019) (K Pcs)
Table Asia Pacific Neuroendocrine Carcinoma Sales Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Neuroendocrine Carcinoma Sales Market Share by Countries
Table Asia Pacific Neuroendocrine Carcinoma Revenue by Countries (2014-2019) (Million US$)
Table Asia Pacific Neuroendocrine Carcinoma Revenue Market Share by Countries (2014-2019)
Figure 2018 Asia Pacific Neuroendocrine Carcinoma Revenue Market Share by Countries
Figure China Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure China Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Japan Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Japan Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Korea Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Korea Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure India Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure India Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Australia Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Australia Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Indonesia Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Indonesia Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Malaysia Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Malaysia Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Philippines Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Philippines Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Thailand Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Thailand Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Vietnam Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Vietnam Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Singapore Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Singapore Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Table Asia Pacific Neuroendocrine Carcinoma Sales by Product (2014-2019) (K Pcs)
Table Asia Pacific Neuroendocrine Carcinoma Sales Market Share by Product (2014-2019)
Figure 2018 Asia Pacific Neuroendocrine Carcinoma Market Share by Product
Table Asia Pacific Neuroendocrine Carcinoma Sales by End User (2014-2019) (K Pcs)
Table Asia Pacific Neuroendocrine Carcinoma Sales Market Share by End User (2014-2019)
Figure 2018 Asia Pacific Neuroendocrine Carcinoma Market Share by End User
Figure Central & South America Neuroendocrine Carcinoma Sales Growth Rate 2014-2019 (K Pcs)
Figure Central & South America Neuroendocrine Carcinoma Revenue Growth Rate 2014-2019 (Million US$)
Table Central & South America Neuroendocrine Carcinoma Sales by Countries (2014-2019) (K Pcs)
Table Central & South America Neuroendocrine Carcinoma Sales Market Share by Countries (2014-2019)
Figure 2018 Central & South America Neuroendocrine Carcinoma Sales Market Share by Countries
Table Central & South America Neuroendocrine Carcinoma Revenue by Countries (2014-2019) (Million US$)
Table Central & South America Neuroendocrine Carcinoma Revenue Market Share by Countries (2014-2019)
Figure 2018 Central & South America Neuroendocrine Carcinoma Revenue Market Share by Countries
Figure Brazil Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Brazil Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Argentina Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Argentina Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Table Central & South America Neuroendocrine Carcinoma Sales by Product (2014-2019) (K Pcs)
Table Central & South America Neuroendocrine Carcinoma Sales Market Share by Product (2014-2019)
Figure 2018 Central & South America Neuroendocrine Carcinoma Market Share by Product
Table Central & South America Neuroendocrine Carcinoma Sales by End User (2014-2019) (K Pcs)
Table Central & South America Neuroendocrine Carcinoma Sales Market Share by End User (2014-2019)
Figure 2018 Central & South America Neuroendocrine Carcinoma Market Share by End User
Figure Middle East and Africa Neuroendocrine Carcinoma Sales Growth Rate 2014-2019 (K Pcs)
Figure Middle East and Africa Neuroendocrine Carcinoma Revenue Growth Rate 2014-2019 (Million US$)
Table Middle East and Africa Neuroendocrine Carcinoma Sales by Countries (2014-2019) (K Pcs)
Table Middle East and Africa Neuroendocrine Carcinoma Sales Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Neuroendocrine Carcinoma Sales Market Share by Countries
Table Middle East and Africa Neuroendocrine Carcinoma Revenue by Countries (2014-2019) (Million US$)
Table Middle East and Africa Neuroendocrine Carcinoma Revenue Market Share by Countries (2014-2019)
Figure 2018 Middle East and Africa Neuroendocrine Carcinoma Revenue Market Share by Countries
Figure GCC Countries Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure GCC Countries Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Turkey Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Turkey Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure Egypt Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure Egypt Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Figure South Africa Neuroendocrine Carcinoma Sales Growth Rate (2014-2019) (K Pcs)
Figure South Africa Neuroendocrine Carcinoma Revenue Growth Rate (2014-2019) (Million US$)
Table Middle East and Africa Neuroendocrine Carcinoma Sales by Product (2014-2019) (K Pcs)
Table Middle East and Africa Neuroendocrine Carcinoma Sales Market Share by Product (2014-2019)
Figure 2018 Middle East and Africa Neuroendocrine Carcinoma Market Share by Product
Table Middle East and Africa Neuroendocrine Carcinoma Sales by End User (2014-2019) (K Pcs)
Table Middle East and Africa Neuroendocrine Carcinoma Sales Market Share by End User (2014-2019)
Figure 2018 Middle East and Africa Neuroendocrine Carcinoma Market Share by End User
Table Pfizer Company Details
Table Pfizer Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2014-2019)
Table Pfizer Recent Development
Table Novartis Company Details
Table Novartis Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2014-2019)
Table Novartis Recent Development
Table Chiasma Company Details
Table Chiasma Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2014-2019)
Table Chiasma Recent Development
Table Ipsen Company Details
Table Ipsen Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2014-2019)
Table Ipsen Recent Development
Table Abbvie Company Details
Table Abbvie Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2014-2019)
Table Abbvie Recent Development
Table Valeant Company Details
Table Valeant Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2014-2019)
Table Valeant Recent Development
Table Jubilant Company Details
Table Jubilant Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2014-2019)
Table Jubilant Recent Development
Table Teva Company Details
Table Teva Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2014-2019)
Table Teva Recent Development
Table F.Hoffmann-La Roche Company Details
Table F.Hoffmann-La Roche Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2014-2019)
Table F.Hoffmann-La Roche Recent Development
Table Advanced Accelerator Company Details
Table Advanced Accelerator Neuroendocrine Carcinoma Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2014-2019)
Table Advanced Accelerator Recent Development
Table Mateon Company Details
Table Lexicon Company Details
Table Global Neuroendocrine Carcinoma Sales Forecast by Regions 2019-2025 (K Pcs)
Table Global Neuroendocrine Carcinoma Sales Market Share Forecast by Regions 2019-2025
Table Global Neuroendocrine Carcinoma Revenue Forecast by Regions 2019-2025 (Million US$)
Table Global Neuroendocrine Carcinoma Revenue Market Share Forecast by Regions 2019-2025
Table Global Neuroendocrine Carcinoma Sales Forecast by Product 2019-2025 (K Pcs)
Table Global Neuroendocrine Carcinoma Sales Market Share Forecast by Product 2019-2025
Table Global Neuroendocrine Carcinoma Revenue Forecast by Product 2019-2025 (Million US$)
Table Global Neuroendocrine Carcinoma Revenue Market Share Forecast by Product 2019-2025
Table Global Neuroendocrine Carcinoma Sales Forecast by End User 2019-2025 (K Pcs)
Table Global Neuroendocrine Carcinoma Sales Market Share Forecast by End User 2019-2025
Figure North America Neuroendocrine Carcinoma Sales Growth Rate Forecast (2019-2025) (K Pcs)
Figure North America Neuroendocrine Carcinoma Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Europe Neuroendocrine Carcinoma Sales Growth Rate Forecast (2019-2025) (K Pcs)
Figure Europe Neuroendocrine Carcinoma Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Asia Pacific Neuroendocrine Carcinoma Sales Growth Rate Forecast (2019-2025) (K Pcs)
Figure Asia Pacific Neuroendocrine Carcinoma Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Central & South America Neuroendocrine Carcinoma Sales Growth Rate Forecast (2019-2025) (K Pcs)
Figure Central & South America Neuroendocrine Carcinoma Revenue Growth Rate Forecast (2019-2025) (Million US$)
Figure Middle East and Africa Neuroendocrine Carcinoma Sales Growth Rate Forecast (2019-2025) (K Pcs)
Figure Middle East and Africa Neuroendocrine Carcinoma Revenue Growth Rate Forecast (2019-2025) (Million US$)
Table Neuroendocrine Carcinoma Value Chain
Table Neuroendocrine Carcinoma Customers List
Table Neuroendocrine Carcinoma Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
世界の神経内分泌腫瘍（NET）治療市場：専門的調査 Neuro Emotional Technique (NET) is a psycho-emotional therapy based on the physiological foundations of stress-related responses. As discovered in the late 1970’s, emotional responses are composed of neuropeptides (amino acid chains) and their receptors, which lie on neurons and other cells of remot…- ソマトスタチンアナログの世界市場：インサイト・予測 Somatostatin analogues stop your body from making too many hormones. They can reduce the symptoms of carcinoid syndrome and may slow down tumour growth.Somatostatin is a protein made naturally in the body. It is made by: a gland in the brain (hypothalamus), the stomach, the pancreas and the bowel. S…
- 肝細胞癌薬の世界市場：インサイト・予測 Hepatocellular Carcinoma Drug is a drug for treating Hepatocellular Carcinoma.The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World. Annual estimates and forecasts are provided for the period 2018 through 2025. Also, a f…
- 基底細胞癌治療の世界市場：市場規模・現状・予測 Basal Cell Carcinoma (BCC) is a form of non-melanocytic skin cancer that arises from basal cells, the small, round cells present in the lower epidermis. Around 85% of BCCs occur on the face, head and neck. BCCs usually do not spread or metastasize to other parts of body, they become life threatening…
- 副腎皮質癌治療の世界市場：市場規模・現状・予測 Adrenocortical carcinoma (ACC) is a rare disease caused by cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. The adrenal glands lie on top of the kidneys. They play a major role in the endocrine system, which is the system that produces and regulates hormones. T…